To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology.

[1]  Joseph Kannarkatt,et al.  Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. , 2017, Journal of oncology practice.

[2]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[3]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[4]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[6]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[7]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[8]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[9]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[10]  F. Marincola,et al.  The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.

[11]  F. Wright,et al.  Impact of lymph node retrieval and pathological ultra‐staging on the prognosis of stage II colon cancer , 2003, Journal of surgical oncology.